MCID: ADR040
MIFTS: 46

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15 17
Pheochromocytoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 71 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 A malignant pheochromocytoma that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to malignant pediatric adrenal gland pheochromocytoma and pheochromocytoma, and has symptoms including tremor, fever and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is NGF (Nerve Growth Factor), and among its related pathways/superpathways are p75(NTR)-mediated signaling and Neurotrophic factor-mediated Trk receptor signaling. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include thyroid, adrenal gland and brain.

Related Diseases for Adrenal Gland Pheochromocytoma

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


tremor, fever, abdominal pain, chest pain, headache

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Doxazosin Approved Phase 3 74191-85-8 3157
5
Phenoxybenzamine Approved Phase 3 59-96-1 4768
6 Calamus Phase 3
7 Antibiotics, Antitubercular Phase 3
8
Isophosphamide mustard Phase 3 100427
9 Anti-Bacterial Agents Phase 3
10
Liposomal doxorubicin Phase 3 31703
11 Antihypertensive Agents Phase 3
12 Adrenergic alpha-1 Receptor Antagonists Phase 3
13 Adrenergic alpha-Antagonists Phase 3
14 Adrenergic Antagonists Phase 3
15 Adrenergic Agents Phase 3
16 Vasodilator Agents Phase 3
17 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
18
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
19
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
21
Carbidopa Approved Phase 2 28860-95-9 34359
22
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
23
Sodium citrate Approved, Investigational Phase 2 68-04-2
24
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
25
Tamoxifen Approved Phase 2 10540-29-1 2733526
26
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
27
nivolumab Approved Phase 1, Phase 2 946414-94-4
28
Olaparib Approved Phase 2 763113-22-0 23725625
29
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
30
Prazosin Approved Phase 2 19216-56-9 4893
31
Dexmedetomidine Approved, Vet_approved Phase 2 113775-47-6 68602 5311068
32
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
33
Ramipril Approved Phase 2 87333-19-5 5362129
34
Atenolol Approved Phase 2 29122-68-7 2249
35
Labetalol Approved Phase 2 36894-69-6 3869
36
Candesartan cilexetil Approved Phase 2 145040-37-5 2540
37
Bisoprolol Approved Phase 2 66722-44-9 2405
38
Propranolol Approved, Investigational Phase 2 525-66-6 4946
39
Pembrolizumab Approved Phase 2 1374853-91-4
40
Ipilimumab Approved Phase 2 477202-00-9
41
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
42
Lenvatinib Approved, Investigational Phase 2 417716-92-8
43
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
44
lanreotide Approved Phase 2 108736-35-2
45
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
46
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
47
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
50 Guadecitabine Investigational Phase 2 929901-49-5

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
8 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Completed NCT01967576 Phase 2 Axitinib (AG-013736)
9 (131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
10 A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
11 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
12 A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
13 A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors Completed NCT00923481 Phase 2 Fostamatinib disodium
14 A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer Completed NCT03165721 Phase 2 SGI-110 (guadecitabine)
15 A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma Completed NCT01635907 Phase 2 Dovitinib
16 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
18 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
19 A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma Recruiting NCT04394858 Phase 2 Olaparib;Temozolomide
20 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
21 The Perioperative Use of Dexmedetomidine and Magnesium Sulfate Compared With Traditional Anesthetic Technique for Open Resection of Pheochromocytoma. Recruiting NCT04320589 Phase 2 Dexmedetomidine;General anesthetic
22 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
23 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
24 Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma Recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
25 A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET. Recruiting NCT04276597 Phase 2 177Lu-DOTATOC
26 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib S-malate
27 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
28 Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors Recruiting NCT00107289 Phase 2
29 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
30 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
31 Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma Active, not recruiting NCT03008369 Phase 2 Lenvatinib
32 A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
33 A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
34 A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) Not yet recruiting NCT04711135 Phase 2 Lutetium [177Lu] oxodotreotide/dotatate
35 Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
36 A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors Terminated NCT00843531 Phase 2 RAD001;erlotinib
37 A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
38 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
39 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
40 Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
41 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
42 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
43 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
44 Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma Recruiting NCT00004847 Phase 1 ([18F]-DOPA);[68Ga]-DOTATATE;([18F]-6F-DA)
45 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
46 A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
47 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
48 Performance of an Omics-signature in the Diagnosis and Prognosis of Endocrine and Primary Hypertension Unknown status NCT02772315
49 Influence of Surgeon-anesthesiologist Collaboration on Patient Outcomes After Pheochromocytoma Surgery Unknown status NCT03158870
50 Evaluation of Stress Hormone Concentration During the Resection of Pheochromocytoma. Comparison of Surgeon - Anesthesiologist - Patient Unknown status NCT00948181

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Metyrosine
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Propranolol
Propranolol Hydrochloride

Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

40
Thyroid, Adrenal Gland, Brain, Heart, Pituitary, Bone, Liver

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 15784)
# Title Authors PMID Year
1
Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect. 61
33493868 2021
2
Re-evaluating 'Surgical Dogma' in the Postoperative Management of Pheochromocytoma/Paragangliomas: Reflecting on the Data Cannot Help but to Bring About Change. 61
33215252 2021
3
A human relevant mixture of persistent organic pollutants (POPs) and perfluorooctane sulfonic acid (PFOS) enhance nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. 61
33309997 2021
4
Comparison of synchronous bilateral transperitoneal and posterior retroperitoneal laparoscopic adrenalectomy: results of a multicenter study. 61
32152673 2021
5
Ginsenoside Rb1 protected PC12 cells from Aβ25-35-induced cytotoxicity via PPARγ activation and cholesterol reduction. 61
33359145 2021
6
Iodination of CART(61-102) peptide: Preserved binding and anorexigenic activity in mice. 61
32678955 2021
7
Enhanced nerve cell proliferation and differentiation on electrically conductive scaffolds embedded with graphene and carbon nanotubes. 61
32441388 2021
8
An Adrenal Incidentaloma Diagnosed as Dopamine-Secreting Pheochromocytoma: A Case Report. 61
32741578 2021
9
Pheochromocytoma/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas. 61
33575936 2021
10
Genetic testing for pheochromocytoma and paraganglioma: SDHx carriers' experiences. 61
33604970 2021
11
Case Report of Fulminant Eosinophilic Myocarditis With Concomitant Pheochromocytoma. 61
33560641 2021
12
Pheochromocytoma as a cause of repeated acute myocardial infarctions, heart failure, and transient erythrocytosis: A case report and review of the literature. 61
33585644 2021
13
A rare pheochromocytoma complicated by cardiogenic shock and posterior reversible encephalopathy syndrome: case report. 61
33598609 2021
14
Pheochromocytoma in a patient presenting with ventricular fibrillation and carotid dissection: a case report. 61
33569530 2021
15
Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience. 61
32072283 2021
16
Pheochromocytoma of the organ of Zuckerkandl. 61
33299507 2021
17
Late diagnosis of metastatic pheochromocytoma in multiple endocrine neoplasia 2B with rapid clinical decline. 61
33541961 2021
18
Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. 61
33303379 2021
19
Management of 3 Cases of Pheochromocytoma During the COVID-19 Pandemic in New York City: Lessons Learned. 61
33447692 2021
20
Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. 61
33586556 2021
21
Acute hypertensive crisis due to newly diagnosed pheochromocytoma in the ninth decade of life: an unusual presentation. 61
33568410 2021
22
A Novel Double RET E768D/L790F Mutation Associated with a MEN2B-Like Phenotype. 61
32546069 2021
23
Laparoscopic transperitoneal adrenalectomy in the large adrenal tumor from single center experience. 61
33522915 2021
24
Neuroprotective roles of HAX-1 in ischemic neuronal injury. 61
33600816 2021
25
Redox proteomics reveals an interdependence of redox modification and location of adhesome proteins in NGF-treated PC12 cells. 61
33465466 2021
26
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. 61
33588146 2021
27
False elevations in urinary metanephrines: under-recognised pitfall with 24-hour urinary volume collection. 61
33541972 2021
28
Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. 61
33549276 2021
29
Probability of positive genetic testing in patients diagnosed with pheochromocytoma and paraganglioma: Criteria beyond a family history. 61
33023754 2021
30
Periodic Blood Pressure Fluctuations in Undiagnosed Pheochromocytoma. 61
32788539 2021
31
[Molecular genetics of human hypertension]. 61
33595671 2021
32
Approach to pheochromocytoma and paraganglioma in children and adolescents: A retrospective clinical study from a tertiary care center. 61
33593626 2021
33
Unexpected obesity, rather than tumorigenesis, in a conditional mouse model of mitochondrial complex II deficiency. 61
33247500 2021
34
Radiopharmaceuticals for Neuroendocrine Tumors. 61
33246637 2021
35
Giant secretory multifocal adrenal myelolipoma: a diagnostic dilemma. 61
33514622 2021
36
Hydrodynamic particle focusing enhanced by femtosecond laser deep grooving at low Reynolds numbers. 61
33462348 2021
37
Silencing PAQR3 protects against oxygen-glucose deprivation/reperfusion-induced neuronal apoptosis via activation of PI3K/AKT signaling in PC12 cells. 61
33249098 2021
38
The longevity gene mIndy (I'm Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms. 61
33491666 2021
39
Cytosine arabinoside induces phosphorylation of histone H2AX in hippocampal neurons via a noncanonical pathway. 61
33290798 2021
40
Propofol protects PC12 cells from cobalt chloride -induced injury by mediating miR-134. 61
33410125 2021
41
[A Case of Adrenal Anastomosing Hemangioma]. 61
33535290 2021
42
Developmental vascular malformations in EPAS1-gain-of-function syndrome. 61
33497361 2021
43
Glucocorticoids attenuate interleukin-6-induced c-Fos and Egr1 expression and impair neuritogenesis in PC12 cells. 61
33454999 2021
44
Oxindole-curcumin hybrid compound enhances the transcription of γ-glutamylcysteine ligase. 61
33508284 2021
45
Safety of outpatient adrenalectomy across 3 minimally invasive approaches at 2 academic medical centers. 61
32409169 2021
46
Aluminum maltolate triggers ferroptosis in neurons: mechanism of action. 61
32900247 2021
47
Inhibition of BACE1, MAO-B, cholinesterase enzymes, and anti-amyloidogenic potential of selected natural phytoconstituents: Multi-target-directed ligand approach. 61
33249607 2021
48
Incidental cardiac findings on somatostatin receptor PET/CT: What do they indicate and are they of clinical relevance? 61
33502695 2021
49
Ectopic ACTH- and/or CRH-Producing Pheochromocytomas. 61
32710791 2021
50
Therapeutic potential and pharmacological activities of β-eudesmol. 61
33449412 2021

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 190)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88294223 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 3
2 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 3
3 COSM90654925 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 3
4 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 3
5 COSM90652830 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.373G>T p.V125F 3:10149819-10149819 3
6 COSM90668341 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.369G>T p.Q123H 3:10149815-10149815 3
7 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 3
8 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 3
9 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 3
10 COSM90669380 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.470T>C p.L157P 3:10149916-10149916 3
11 COSM90655004 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.376C>T p.R126W 3:10149822-10149822 3
12 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 3
13 COSM90652721 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.368A>G p.Q123R 3:10149814-10149814 3
14 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 3
15 COSM90657160 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 3
16 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 3
17 COSM90653943 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>G p.K118E 3:10149798-10149798 3
18 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 3
19 COSM90652730 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 3
20 COSM90664073 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.341-3225T>G p.? 3:10146562-10146562 3
21 COSM88306166 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 3
22 COSM90660753 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 3
23 COSM90648957 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.359G>A p.R120Q 3:10149805-10149805 3
24 COSM88299307 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 3
25 COSM93233747 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 3
26 COSM145017657 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.626G>A p.R209Q 17:7674220-7674220 3
27 COSM145266028 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.232G>C p.G78R 17:7676020-7676020 3
28 COSM106100323 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 3
29 COSM142876232 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 3
30 COSM144013367 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.710G>A p.R237Q 17:7674220-7674220 3
31 COSM143370869 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.626G>A p.R209Q 17:7674220-7674220 3
32 COSM93183630 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
33 COSM144349981 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.188C>T p.T63I 17:7676064-7676064 3
34 COSM142837352 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
35 COSM145062246 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.188C>T p.T63I 17:7676064-7676064 3
36 COSM106310936 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
37 COSM88205586 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
38 COSM144310203 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.626G>A p.R209Q 17:7674220-7674220 3
39 COSM87898351 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
40 COSM112301864 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 3
41 COSM105901626 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
42 COSM112253622 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
43 COSM111807159 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 3
44 COSM144241338 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.340+5G>C p.? 17:7676020-7676020 3
45 COSM144701288 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.188C>T p.T63I 17:7676064-7676064 3
46 COSM143076323 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
47 COSM142560281 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.626G>A p.R209Q 17:7674220-7674220 3
48 COSM112007960 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
49 COSM112518504 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3
50 COSM93438796 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 3

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.78 NGF BDNF
2
Show member pathways
10.41 NGF BDNF

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neuron differentiation GO:0045664 9.4 NGF BDNF
2 positive regulation of macroautophagy GO:0016239 9.37 TRIM13 BNIP3
3 neurotrophin TRK receptor signaling pathway GO:0048011 9.32 NGF BDNF
4 nerve development GO:0021675 9.26 NGF BDNF
5 nerve growth factor signaling pathway GO:0038180 9.16 NGF BDNF
6 positive regulation of collateral sprouting GO:0048672 8.96 NGF BDNF
7 peripheral nervous system development GO:0007422 8.8 SERPINI1 NGF BDNF

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor receptor binding GO:0005163 8.62 NGF BDNF

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....